Clinical Trial Update: Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating docetaxel plus lycopene in chemotherapy-naïve, castration-resistant prostate cancer; study completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Lycopene (lycopene)

Snippet

Sponsor: University of California, Irvine | Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2018-06-04